Compare Celestica Inc (CLS) vs Johnson & Johnson (JNJ) Price & Performance

CLS trades at $339.46, up 7.91% in 24 hours, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS of $2.54 beat estimates, and revenue growth is driven by AI infrastructure demand. The company completed a $3 billion equity offering to fund expansion, though this may cause near-term dilution. Support levels are near $309, with resistance at $313.

Outlook is positive due to robust earnings beats and AI-driven growth, but risks include equity dilution and premium valuation. Analyst consensus is bullish with a $466.50 price target, indicating 37% upside. Investors should weigh growth potential against execution risks and market volatility.

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.